Menu
Explore Our Trials
Gateway for Cancer Research is one of the only nonprofits that exclusively funds innovative Phase I and Phase II cancer clinical trials for patients of all ages, regardless of cancer type. At the forefront of research and discovery, these early-phase trials are the first step in evaluating new cancer drugs, treatments, and therapies.
Results 31-40 of 64
Lung Cancer
Phase 2 trial of the fatty acid synthase (FASN) inhibitor TVB-2640 for advanced KRAS mutant non-small cell lung cancer (NSCLC)
Phase 2 trial of the fatty acid synthase (FASN) inhibitor TVB-2640 for advanced KRAS mutant non-small cell lung cancer (NSCLC) Summary: Non-small cell lung cancer (NSCLC) with a mutation called KRAS occurs in approximately 40,000 patients in the U.S. each year. Patients with the KRAS mutation have a particularly poor prognosis with a 5-year survival […]
David Gerber, MD
University of Texas Southwestern Medical Center
Brain Cancer
Pharmacological ascorbate combined with radiation and temozolomide in GBM
Pharmacological ascorbate combined with radiation and temozolomide in GBM Summary: Glioblastoma multiforme (GBM) is the most common brain tumor in adults. It is highly aggressive and almost uniformly fatal. Despite treatment, most patients only survive 14 to 16 months after diagnosis and the 5-year survival is less than 10%. New treatment strategies are desperately needed […]
Bryan Allen, MD, PhD
University of Iowa
Brain Cancer
A Phase 1 Study of M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL- 12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma
A Phase 1 Study of M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL- 12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma Summary: Gliomas are the most common brain tumor, with glioblastoma multiforme (GBM) being one of the most fatal and treatment-resistant cancers. Survival and time to progression have changed minimally in […]
James Markert, MD, MPH
University of Alabama at Birmingham
Cervical Cancer
Development of an LMIC-adapted Thermoablation Prototype and Treatment Protocol for Cervical Pre-Cancer
Development of an LMIC-adapted Thermoablation Prototype and Treatment Protocol for Cervical Pre-Cancer Summary: Over 250,000 women die each year of cervical cancer in low-to-middle income countries (LMIC). Nearly all cases result from infections from the human papillomavirus (HPV) which develops into cervical precancer. In order to reduce the burden of cervical cancer, precancerous lesions (cervical […]
Miriam Cremer, MD, MPH
Cleveland Clinic Foundation
All Cancers
Mitochondrial-Targeted Gamitrinib for Cancer Therapy
Mitochondrial-Targeted Gamitrinib for Cancer Therapy Summary: There have been impressive clinical responses in select tumors to targeted therapy, but for most cancers the gains are short-lived, and the cancer progresses. It has been found that a protein called Hsp90 chaperone is over abundant in cancer cells. The Hsp90 chaperones are responsible for stabilizing proteins and […]
Dario Altieri, MD
The Wistar Institute
Gynecologic Cancer
Targeting adaptive changes following anti-angiogenesis therapy in ovarian cancer
Targeting adaptive changes following anti-angiogenesis therapy in ovarian cancer Summary: Epithelial ovarian cancer has the highest mortality rate of all gynecological malignancies. Although there have been improvements in the treatment of ovarian cancer, they have been modest. This is partly due to the fact that ovarian cancer is frequently not diagnosed until it has progressed […]
Shannon Westin, MD, MPH, FACOG
MD Anderson Cancer Center
Prostate Cancer
Impact of Cytoreductive Radical Prostatectomy on Oncologic and Quality of Life Outcome in Men with Newly Diagnosed Metastatic Prostate Cancer
Impact of Cytoreductive Radical Prostatectomy on Oncologic and Quality of Life Outcome in Men with Newly Diagnosed Metastatic Prostate Cancer Summary: Prostate is the second most common non-skin cancer diagnosed and the second leading cause of cancer death in men. Furthermore, approximately 16% of prostate cancer patients present with late-stage disease. There is no effective […]
Isacc Kim, MD, PhD, MBA
Yale University
Gastrointestinal Cancer
Perioperative tadalafil and influenza vaccination in cancer patients undergoing major surgical resection of a primary abdominal malignancy
Perioperative tadalafil and influenza vaccination in cancer patients undergoing major surgical resection of a primary abdominal malignancy Summary: Surgery is the mainstay of therapy for most solid tumors but even with complete removal of the tumor, many patients harbor microscopic residual tumor cells and ultimately die of relapse disease. This research group has demonstrated that […]
Rebecca Auer, MD, MSc
Ottawa Hospital Research Institute, Canada
Solid Tumors
Prophylactic Cement Augmentation for Patients at High Risk for Developing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery With Solid Tumors and Spinal Metastases
Prophylactic Cement Augmentation for Patients at High Risk for Developing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery With Solid Tumors and Spinal Metastases Summary: Up to 40% of all cancer patients develop metastatic disease involving the spine. This can severely impact patients’ quality of life by causing pain, weakness, bowel and bladder dysfunction, paralysis, […]
Amol Ghia, MD
MD Anderson Cancer Center
Blood Cancer
A phase I/II study of ARGX-110 in patients with relapsed/refractory acute myeloid leukemia
A phase I/II study of ARGX-110 in patients with relapsed/refractory acute myeloid leukemia Summary: Acute myeloid Leukemia (AML) is an aggressive and fatal blood cancer and while standard chemotherapy can induce a complete remission in 50 to 75% of younger patients, the majority of patients eventually relapse and die of recurrent disease. This is especially […]
Adrian Ochsenbein, MD
University Hospital, Inselspital
